Mantle cell lymphoma is a rare and aggressive form of non-Hodgkin lymphoma that often begins with slow growth in lymph nodes before progressing to rapid growth and widespread disease. Diagnosis frequently occurs at an advanced stage, potentially involving the gastrointestinal tract, spleen, and bone marrow, and most patients are diagnosed between 60 and 70 years of age. The retrospective study used linked Ontario health administrative records from the Institute for Clinical Evaluative Sciences, including data from the Ontario Cancer Registry, to examine patients who were at least 65 at diagnosis and had not received an autologous stem cell transplant.

Among the 754 included patients, the median age was 76 years, with an interquartile range of 71 to 82, and 56.4% were at least 75. Men represented 71.1% of the cohort, and 22.4% of patients with recorded collaborative staging had Stage IV disease at diagnosis. Collaborative stage was missing for 64.1% of the cohort, so the available stage distribution does not describe the entire population. Mean follow-up was 36.1 months, with a standard deviation of 31.1 months. The analysis excluded patients younger than 65, those who received an autologous stem cell transplant, and those with incomplete or invalid administrative records. The design therefore describes a population generally considered ineligible for intensive chemotherapy and transplantation in Ontario practice, rather than directly measuring the clinical decision for every individual participant.

Annual diagnoses remained relatively steady, ranging from 76 to 91 new cases between 2013 and 2021. As Ontario’s population aged 65 and older increased, the estimated crude incidence fell from 0.0425 cases per 1,000 people in 2013 to 0.0332 per 1,000 in 2021. The 2013 estimate had a 95% confidence interval of 0.0344 to 0.0524 per 1,000, while the 2021 estimate had an interval of 0.0269 to 0.0408. This pattern describes a population-rate change over the study period rather than a demonstrated reduction in the underlying number of new diagnoses. The retrospective design could not establish why the rates changed, and the confidence intervals overlapped across annual estimates.

Systemic treatment was initiated in 540 patients, or 71.6% of the cohort, while 214 received no systemic therapy during follow-up. Among treated patients, 391 received only first-line therapy, 125 received second-line therapy without a third line, and 24 reached third-line treatment. Bendamustine plus rituximab was the most common first-line regimen, used in 414 patients, or 76.7% of those treated. R-CHOP accounted for 10.0%, R-CVP for 4.3%, and other first-line regimens for 7.6%. Rituximab maintenance after first-line induction was given to 277 patients, representing 51.3% of the treated group, while 168 patients, or 22.3% of the full cohort, received local radiotherapy. Because these were descriptive counts, the study did not test whether the use of maintenance rituximab improved survival.

The first-line regimen was generally initiated soon after diagnosis: median time from diagnosis to treatment was 1.64 months, with an interquartile range of 0.99 to 3.88 months. Median recorded treatment duration was 12.8 months for patients receiving rituximab maintenance and 4.70 months for those without maintenance. Among the 149 patients who received second-line treatment, ibrutinib was used in 109 cases, or 73.2%, and bortezomib-based therapy in 8, or 5.4%. Median time from diagnosis to second-line treatment was 21.6 months, with an interquartile range of 11.1 to 38.9 months. Recorded second-line treatment lasted a median of 2.14 months, including 2.07 months for ibrutinib. These durations represent the interval between the first and last recorded treatment within each line and do not by themselves establish why treatment ended.

Following first-line treatment, 212 patients died before beginning second-line therapy, accounting for 39.3% of those receiving first-line systemic treatment. Of the 149 patients who reached second-line treatment, 102 died before third-line treatment, or 68.5%. Seven of the first-line deaths were classified as COVID-19-related, as were six deaths after second-line treatment. The investigators estimated median time to next treatment or death at 2.62 years, with a 95% confidence interval of 2.24 to 3.01 years. Patients whose first-line treatment was bendamustine plus rituximab had the longest estimated time to next treatment or death, at 2.85 years with a 95% confidence interval of 2.54 to 3.62, compared with 1.74 years for R-CHOP and 0.90 years for R-CVP. These unadjusted comparisons describe observed outcomes and do not establish that any regimen caused the differences.

Median overall survival after first-line treatment initiation was longest among patients receiving bendamustine plus rituximab, at 4.02 years with a 95% confidence interval of 3.23 to 4.72, compared with 2.67 years for R-CHOP, whose confidence interval was wide at 1.52 to 5.17 years. Median survival across all first-line treatments was 3.51 years, with a 95% confidence interval of 2.89 to 4.03. Age was associated with survival: patients aged 65 to 74 had a median of 5.95 years after first-line treatment, with a 95% confidence interval of 4.26 to 8.01, whereas those aged 75 or older had a median of 2.49 years, with an interval of 2.11 to 2.82. In second-line treatment, median survival was 0.50 years for ibrutinib and 0.60 years across all second-line regimens. Because the study was retrospective and unadjusted, differences cannot be attributed solely to age, regimen selection, disease severity, comorbidity, or other clinical factors.

The findings also illustrate how administrative data were used to assess outcomes in a population with limited treatment options. Progression-free survival could not be measured reliably because health administrative records do not consistently capture progression, so time to next treatment or death served as a pragmatic surrogate. This endpoint combines subsequent treatment with death and therefore differs from progression-free survival. Censoring at the end of the study may have limited assessment of patients diagnosed near 2021, and Ontario-specific funding and clinical practices may limit generalizability to other provinces. Administrative data also may not capture every treatment delivered through compassionate programs, although the investigators expected that omission to have little effect on the analysis. The linked population-level data nevertheless captured nearly all registry-diagnosed cases, providing a broad view of care delivered in routine practice. The study identifies an unmet need for more effective treatments for older patients with mantle cell lymphoma who are ineligible for autologous stem cell transplantation.

Subject of Research: Real-world treatment patterns and survival in older transplant-ineligible mantle cell lymphoma patients in Ontario

Article Title: Real‐World Treatment Patterns, Burden of Illness, and Survival of Autologous Stem Cell Transplant‐Ineligible Patients With Mantle Cell Lymphoma in Ontario, Canada

Article References: George, S., Seung, S. J., Thibault, S., Wong, A., Hamilton, M. A., & Prica, A. (2026). Real‐World Treatment Patterns, Burden of Illness, and Survival of Autologous Stem Cell Transplant‐Ineligible Patients With Mantle Cell Lymphoma in Ontario, Canada. eJHaem, 7(5), Article e70384. https://doi.org/10.1002/jha2.70384

Image Credits: AI Generated

DOI: 10.1002/jha2.70384

Keywords: mantle cell lymphoma, Ontario, older adults, autologous stem cell transplant, ibrutinib, bendamustine, rituximab, real-world evidence, population-based study, overall survival, Real, World

In a study published in Frontiers in Cellular Neuroscience, a team led by Matteo Tartaglia and Myriam Catalano of Sapienza University of Rome, working with colleagues at the CNR Institute of Biomedical Technologies and IRCCS Neuromed, built a laboratory system that reproduces demyelination and recovery in a dish. The work centers on ibrutinib, an irreversible Bruton’s tyrosine kinase inhibitor best known as a blood cancer drug, and asks a deceptively simple question: when ibrutinib helps myelin repair, is it acting on the neurons, on the immune cells, or on the messages passed between them?

To answer it, the researchers needed a model that could sustain real myelination. They isolated spinal cord and brain cortex tissue from postnatal mouse pups aged zero to two days, dissociating the tissue into primary mixed cultures that contained neurons, oligodendrocyte lineage cells, microglia, and astrocytes in proportions resembling the native tissue. By day 35 in vitro, the cultures were floridly myelinated: roughly 59 percent of spinal cord neurons and 52 percent of cortical neurons carried myelin basic protein around their neurites, verified in three dimensions using z-stack confocal imaging and a strict colocalization criterion. Importantly, the team found that the window for study was narrow. By day 45, myelination declined substantially in both culture types, so day 35 became the sweet spot for perturbation experiments.

The demyelinating insult came from lysophosphatidylcholine, or LPC, a detergent-like lipid that disrupts the myelin sheath directly, triggering a secondary immune response that mimics key pathological features of multiple sclerosis. Twenty-four hours of LPC treatment slashed myelination in spinal cord cultures from about 62 percent to 29 percent, and in cortical cultures from roughly 53 percent to 23 percent. Over the following week, the cultures tried to heal themselves. The cortical cultures managed an essentially complete recovery on their own, but the spinal cord cultures only partially rebounded, reaching about 50 percent of neurons remyelinated. That incomplete spontaneous repair made the spinal cord preparations the ideal test bed for a drug that might accelerate the process.

Ibrutinib delivered that acceleration. Applied one day after LPC exposure for 24 hours, the drug drove spinal cord cultures to remyelination levels indistinguishable from healthy controls, while offering no additional benefit in the cortex, where spontaneous repair was already sufficient. This pattern matters mechanistically: Bruton’s tyrosine kinase is a cytoplasmic signaling enzyme expressed in immune cells and, within the central nervous system, mainly by microglia and other CD11b-positive myeloid cells, but not by oligodendrocytes themselves. Any pro-remyelinating effect of blocking it therefore cannot be a direct action on the myelin-forming cells. It must be mediated through the immune compartment, most plausibly through microglia, which adopt an inflamed phenotype after demyelination and can either amplify damage or support repair.

To pin down that mediation, the team turned to BV2 cells, a murine microglia-like cell line. Since LPC alone did not induce a detectable inflammatory program in these cells, which lack neurons and oligodendrocytes, the researchers used lipopolysaccharide, or LPS, to impose a strongly pro-inflammatory state. They then collected the small extracellular vesicles, membrane-enclosed nanoparticles typically around 160 nanometers in diameter, that the cells released into the culture medium. Extracellular vesicles have become a focus of neuroimmunology because their cargo reflects the state of the donor cell and can reprogram recipient cells. Earlier work has shown that microglial vesicles can influence oligodendrocyte precursor cells and astrocytes at myelin lesions, sometimes helping and sometimes hindering repair.

The results were striking. Ibrutinib reduced the sheer number of vesicles shed by inflamed BV2 cells without changing their size profile, suggesting it interferes with the vesicle-release machinery itself. More importantly, it changed what the vesicles carried. Quantitative PCR revealed that vesicles from inflamed microglia treated with ibrutinib contained significantly more miR-223, a microRNA with established regenerative credentials, while levels of the pro-inflammatory miR-155 were unchanged. miR-223 has been shown in previous studies to promote debris clearance and regenerative myeloid phenotypes in the demyelinated nervous system, and it is upregulated in patients with multiple sclerosis compared with healthy individuals. When the researchers applied vesicles from LPS-plus-ibrutinib-treated microglia to demyelinated spinal cord cultures, remyelination improved just as it had with direct ibrutinib treatment. Crucially, the benefit persisted even when endogenous vesicle release in the cultures was blocked with calpeptin, confirming that the effect came from the applied vesicles rather than from modulating the recipient cells’ own vesicle traffic.

The final piece of the puzzle pointed to a specific molecular target. Searching the miRCarta database, the team identified stathmin-1, encoded by the STMN1 gene, as a predicted target of miR-223. Stathmin-1 is a microtubule-destabilizing protein that inhibits tubulin polymerization and stiffens the cytoskeleton, and it is overexpressed in oligodendrocytes from patients with multiple sclerosis, where it may obstruct the cellular remodeling that remyelination demands. In spinal cord cultures recovering from LPC injury, ibrutinib treatment significantly reduced STMN1 expression. The emerging model is elegant: blocking Bruton’s tyrosine kinase in inflamed microglia reshapes the cargo of their extracellular vesicles, enriching them with miR-223, which then reaches oligodendrocyte lineage cells and suppresses a cytoskeletal brake on repair.

The study also carries a practical innovation. By adapting an existing protocol to postnatal mice rather than rat embryos, the researchers created a myelinating culture system that better aligns with the 3Rs principles for animal research while faithfully reproducing the cellular composition of spinal cord and cortex. The nearly three-to-one ratio of non-neuronal to neuronal cells in their cultures matched estimates from mouse, monkey, and human nervous system tissue, lending the model physiological credibility. Whether the postnatal system reveals dynamics that embryonic cultures mask, such as the age-dependent decline in myelination after day 40, remains to be explored in disease models.

For the multiple sclerosis field, the implications are timely. Several Bruton’s tyrosine kinase inhibitors are in clinical development, with phase 2 trials of brain-penetrant candidates already reporting safety and efficacy signals in relapsing disease. Those drugs are thought to work largely by damping B cell and microglial activation, but this study suggests a second, reparative arm: beyond suppressing inflammation, BTK inhibition may actively retune microglial communication to favor remyelination. The authors are careful to frame their findings as preliminary, derived from in vitro systems and a microglia-like cell line. Yet the demonstration that the pro-repair signal travels in vesicles, and that a specific microRNA-protein axis may mediate it, opens a concrete path toward therapies that do not merely halt demyelination but hand the nervous system the molecular tools to rebuild what it has lost.

Subject of Research: Ibrutinib-mediated acceleration of remyelination through microglial extracellular vesicle signaling

Article Title: Neuron myelination is accelerated by Bruton’s tyrosine kinase inhibition via microglial extracellular vesicles

Article References: Tartaglia, M., Ioni, A., De Luca, M., Vilardo, L., D’Agnano, I., Conte, A., Limatola, C., & Catalano, M. (2026). Neuron myelination is accelerated by Bruton’s tyrosine kinase inhibition via microglial extracellular vesicles. Frontiers in Cellular Neuroscience, 20, Article 1864654. https://doi.org/10.3389/fncel.2026.1864654

Image Credits: AI Generated

DOI: 10.3389/fncel.2026.1864654

Keywords: multiple sclerosis, remyelination, ibrutinib, Bruton's tyrosine kinase, microglia, extracellular vesicles, miR-223, stathmin-1, oligodendrocytes, demyelination, neuroinflammation, spinal cord cultures

Chronic lymphocytic leukaemia, or CLL, is a malignancy characterised by the progressive accumulation of monoclonal lymphocytes bearing a distinctive immunophenotype — cells that are CD5-positive, CD19-positive, CD20-dim, CD23-positive and express dim surface immunoglobulin — in the peripheral blood, bone marrow and lymphoid tissues. Unlike many other chronic lymphoproliferative disorders, CLL is defined as much by its immunological consequences as by its malignant ones. Patients frequently present with immune disturbances and recurrent infections, a feature that makes the disease particularly dangerous in the era of a novel respiratory virus. The leukaemic cells crowd out functional immune components, and the humoral arm of the immune system is often left strikingly weakened.

The patient in this report had been diagnosed with CLL four years before she presented with fever. For the two years preceding her COVID-19 illness, she had been receiving ibrutinib, a targeted Bruton tyrosine kinase inhibitor used as maintenance therapy. While ibrutinib has transformed the management of CLL, it adds another layer of immunosuppression to a disease already defined by immune dysfunction. When her symptoms began, a computed tomography scan of the chest revealed a pattern of ground-glass opacities, the hazy radiological signature familiar to clinicians throughout the pandemic, and RT-PCR testing confirmed SARS-CoV-2 infection.

What followed was a clinical course that departed sharply from the expected trajectory. Two weeks after the patient had clinically recovered, repeat RT-PCR testing remained positive. Twenty-eight days later, she returned to medical attention with fever and weakness. On admission, her clinicians discontinued ibrutinib, a common practice for patients with COVID-19 intended to minimise potential drug-related complications and reduce the burden of immunosuppression. She was treated with dexamethasone to manage inflammation and remdesivir as antiviral therapy, both standard interventions for hospitalised COVID-19 patients aimed at curbing viral replication and blunting the cytokine-driven tissue damage that characterises severe disease.

Despite this conventional therapeutic arsenal, the virus would not retreat. Serial RT-PCR tests performed on nasopharyngeal aspirates continued to detect the SARS-CoV-2 genome, with positivity persisting up to 127 days after symptom onset. Throughout this period, the patient remained under quarantine and home observation. Laboratory findings captured the depth of her illness: a white blood cell count of 50 × 10⁹ per litre with 88 percent lymphocytes, reflecting the leukaemic burden; a C-reactive protein level of 200 mg/L and an erythrocyte sedimentation rate of 119 mm/hour, markers of vigorous systemic inflammation; and elevated liver enzymes, with alanine aminotransferase at 87 U/L and aspartate aminotransferase at 75 U/L. Eventually, on day 127, her oxygen saturation declined, and she died in the intensive care unit.

The authors of the report attribute this extraordinary duration of viral shedding to the profound immunodeficiency associated with CLL, further compromised by ongoing chemotherapy and ibrutinib therapy. Central to this vulnerability is hypogammaglobulinemia, a hallmark of CLL in which levels of protective antibodies — IgG, IgA and IgM — fall below the thresholds needed for effective host defence. These immunoglobulins are crucial for neutralising SARS-CoV-2 and preventing its dissemination within the body. When the humoral immune system cannot mount a competent antibody response against the virus, viral replication proceeds unchecked, and shedding continues for months rather than weeks. The patient’s failure to seroconvert, noted by the authors, aligns with a growing body of evidence showing that CLL patients mount suboptimal antibody responses to SARS-CoV-2 infection.

This immunological failure helps explain a broader and troubling pattern. Early reports from China indicated that individuals with cancer are more susceptible to SARS-CoV-2, although initial data on the prevalence and features of COVID-19 across different cancers, including CLL, were limited. Subsequent studies have shown that patients with CLL are more likely to experience severe COVID-19, with higher rates of hospitalisation, intensive care unit admission and mortality compared to the general population. Advanced age compounds the risk, and this patient’s 69 years, combined with ongoing chemotherapy, placed her in a particularly precarious position. Prolonged viral shedding has been documented in other immunocompromised individuals as well, but the distinguishing feature of this case, according to the authors, is the demonstration that early cessation of targeted therapy combined with standard antiviral and corticosteroid administration was entirely insufficient to halt continuous viral replication, ultimately leading to fatal hypoxemia by day 127.

The case also raises uncomfortable questions about the limits of standard COVID-19 therapy in immunocompromised hosts. Remdesivir, a nucleotide analogue prodrug that inhibits viral RNA-dependent RNA polymerase, and dexamethasone, a corticosteroid that dampens the inflammatory cascade, were developed and validated largely in populations with intact immune systems. In a patient who cannot generate neutralising antibodies, the report suggests, these treatments may not suffice to achieve viral clearance. The authors point instead to monoclonal antibodies such as casirivimab and imdevimab, which have shown promise in facilitating rapid viral clearance in CLL patients grappling with persistent infections. By supplying exogenous neutralising antibodies, such therapies can in principle substitute for the humoral response the patient’s own body cannot mount, offering a potential therapeutic avenue where conventional regimens fall short.

Supportive measures aimed at correcting the underlying antibody deficiency may hold similar promise. The authors highlight intravenous immunoglobulin infusions, which replenish circulating IgG and can provide passive immunity against a broad range of pathogens, as an intervention that may improve outcomes among CLL patients infected with SARS-CoV-2. Cited literature includes a reported case of long-lasting SARS-CoV-2 infection with post-COVID-19 chronic interstitial pneumonia in a CLL patient treated successfully with intravenous immunoglobulin, suggesting that addressing hypogammaglobulinemia directly can alter the course of otherwise intractable infections. Robust monitoring of viral shedding in such patients is also emphasised, both to guide therapy and to minimise potential transmission risks from prolonged carriers — a public health consideration, since immunocompromised individuals who harbour replicating virus for months are also environments in which new variants can emerge.

The report’s authors conclude that the prevalence, clinical characteristics and outcomes of COVID-19 in CLL patients have yet to be fully established, and that preliminary data from large patient series remain valuable for understanding and managing these cases. Their central message is a call for tailored strategies that go beyond remdesivir and dexamethasone, particularly given the high mortality linked to comorbidities in this population. For clinicians, the case is a reminder that a positive RT-PCR test in an immunocompromised patient is not merely a lingering molecular echo of a resolved infection; it can reflect genuinely ongoing viral replication. For virologists, it is a vivid demonstration of the delicate equilibrium between host immunity and viral persistence — an equilibrium that, when the immune system fails, can stretch a two-week illness into a 127-day ordeal with a fatal end.

Subject of Research: Prolonged SARS-CoV-2 RNA shedding in a chronic lymphocytic leukaemia patient with impaired antibody responses

Article Title: Persistent SARS‐CoV‐2 RNA Positivity in a Chronic Lymphocytic Leukaemia Patient for 127 Days After Disease Onset: A Case Report

Article References: Khamseh, F., Moghtader‐Mojdehi, A.-H., Nemati, Z., & Haghighi, M. (2026). Persistent SARS ‐ CoV ‐2 RNA Positivity in a Chronic Lymphocytic Leukaemia Patient for 127 Days After Disease Onset: A Case Report. Respirology Case Reports, 14(10), Article e70767. https://doi.org/10.1002/rcr2.70767

Image Credits: AI Generated

DOI: 10.1002/rcr2.70767

Keywords: SARS-CoV-2, chronic lymphocytic leukaemia, viral shedding, immunodeficiency, hypogammaglobulinemia, ibrutinib, remdesivir, dexamethasone, RT-PCR, monoclonal antibodies, COVID-19, case report

CD19 has become the single most important target in B-cell malignancy therapy. Chimeric antigen receptor T-cell therapies, bispecific antibodies, and antibody-drug conjugates overwhelmingly depend on the dense, consistent expression of CD19 on the surface of malignant B lymphocytes. Yet relapse after CD19-directed immunotherapy is common, and one of the best-documented mechanisms of that relapse is the loss or masking of surface CD19. Tumor cells that downregulate the antigen effectively become invisible to the therapy, resuming their growth once the immune pressure has been evaded. Understanding what controls CD19 abundance at the cell surface, and how clinical drugs might stabilize it, is therefore a question of substantial therapeutic consequence. The new work addresses that question directly, and its answer involves an unlikely player.

Matriptase, encoded by the ST14 gene, is a type II transmembrane serine protease with a well-established role in epithelial biology. It is best known for initiating proteolytic cascades that regulate barrier function, filaggrin processing, and growth factor signaling in skin and other epithelial tissues. Its dysregulation has been implicated in epithelial cancers, where excessive matriptase activity can promote invasion and metastasis. Its role in lymphoid malignancies, by contrast, has been far less explored. The new study now places matriptase at the center of a drug-responsive circuit in malignant B cells, where it appears to act on the fate of CD19 itself, preserving the antigen in its extracellular, antibody-accessible form rather than allowing it to be shed, internalized, or otherwise lost from the cell surface.

The central observation is a causal chain. When malignant B cells are exposed to ibrutinib, the drug does more than inhibit BTK signaling; it triggers an increase in matriptase activity or abundance. That protease, in turn, acts to maintain extracellular CD19. In practical terms, cells treated with the drug retain the surface target that CAR-T cells and CD19-directed antibodies recognize, whereas cells in which the matriptase arm of this circuit is disrupted lose that protection and become prone to antigen escape. The authors frame this as a mechanism by which ibrutinib limits antigen escape in B-cell malignancy, a framing that carries immediate translational weight because ibrutinib is already approved and widely used in chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell disorders.

The clinical logic of the finding is compelling. Ibrutinib and CD19-directed immunotherapies are frequently considered in overlapping patient populations, and sequencing decisions between BTK inhibition and cellular immunotherapy are often made empirically. If ibrutinib treatment stabilizes surface CD19, then a period of BTK inhibition before leukapheresis or CAR-T infusion could, in principle, improve the quality of the target presented to the engineered cells, reducing the likelihood that the manufactured product encounters antigen-low tumor cells. Conversely, the study raises a caution: interventions or tumor adaptations that suppress matriptase might undermine CD19 display and thereby predispose patients to escape from CD19-directed therapies, even when the malignant cells remain otherwise sensitive to cytotoxic pressure.

Antigen escape is not a single mechanism but a family of them. Tumor cells can mutate the CD19 locus, introduce truncating mutations, alter exon splicing so that the epitope is lost while the protein remains, internalize the antigen faster than it is replaced, or shield it from antibody binding through changes in the membrane microenvironment. Each of these routes has been documented in patients relapsing after CD19 CAR-T therapy. What the new study contributes is the idea that the extracellular maintenance of CD19 is an actively regulated process, one that a protease can influence and that an approved drug can modulate. That reframing matters because it converts antigen loss from an apparently random escape event into a process with identifiable molecular control points that might be monitored and manipulated.

The mechanistic details also connect two previously separate strands of B-cell biology. BTK signaling sits at the heart of the B-cell receptor pathway, and its chronic engagement is a hallmark of many B-cell malignancies, particularly those dependent on active B-cell receptor signaling such as chronic lymphocytic leukemia and mantle cell lymphoma. Ibrutinib’s inhibition of BTK disrupts survival signals and drives malignant cells toward apoptosis. The new data suggest that this well-characterized pharmacologic action has a second, previously underappreciated consequence: a protease-mediated remodeling of the tumor cell surface that favors target retention. In effect, a drug designed to weaken the tumor may simultaneously make the tumor easier to see for the immune system, an unintended benefit that could be exploited deliberately.

For researchers in the immunotherapy field, the study suggests several lines of immediate follow-up. Measuring matriptase activity in patient samples before CD19-directed therapy could reveal whether protease status predicts who is at risk of antigen-negative relapse. Pharmacologic or genetic modulation of matriptase in preclinical models could test whether enhancing its activity further improves CD19 persistence under immune pressure. Combination trials pairing ibrutinib with CD19 CAR-T or bispecific antibodies are already underway for various indications, and the new mechanism provides a biological rationale for such combinations that goes beyond simple additive cytotoxicity. Biomarker strategies that track surface CD19 density longitudinally during BTK inhibition could also help clinicians time cellular therapy infusions for maximal target availability.

There are, of course, important caveats. Matriptase is a protease with pleiotropic effects, and its activity in epithelial cancers has often been associated with tumor progression, so any therapeutic strategy aimed at boosting its function in lymphoid malignancy would need to account for tissue-specific context and potential off-tumor consequences. The relationship between ibrutinib exposure, matriptase activation, and CD19 maintenance will also need to be validated across the full diversity of B-cell malignancies, since the biology of chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and mantle cell lymphoma differ substantially in their dependence on BTK signaling and their patterns of antigen expression. Clinical outcomes, not only cell-culture measurements, will ultimately determine whether the mechanism translates into lower rates of antigen-escape relapse in treated patients.

Even with those qualifications, the study adds a genuinely new concept to the immunotherapy conversation: that the target itself can be pharmacologically defended. Much of the effort in overcoming antigen escape has focused on the therapeutic side, through multi-antigen CAR constructs targeting CD19 together with CD20 or CD22, or through sequential and dual-targeting strategies. The alternative approach suggested here is to act on the tumor cell so that it continues to display the antigen the therapy needs. If ibrutinib-triggered matriptase activity proves to be a reliable and safe lever for maintaining extracellular CD19, it would represent a rare example of an approved small-molecule drug being repurposed, at least conceptually, as a target-preservation agent for cellular immunotherapy. In a field where antigen loss remains one of the leading causes of treatment failure, that is an idea with the potential to reshape how BTK inhibitors and CD19-directed therapies are sequenced and combined in the clinic.

Subject of Research: Ibrutinib-triggered matriptase activity maintains extracellular CD19 and limits antigen escape in B-cell malignancy

Article Title: Ibrutinib-triggered matriptase maintains extracellular CD19 and limits antigen escape in B-cell malignancy

Article References: Lu, X.-J., Lai, H.-F., Hung, Y.-S., Wang, Y.-J., Wu, S.-C., Wang, J.-K., Wu, Y.-Y., & Chiu, Y.-L. (2026). Ibrutinib-triggered matriptase maintains extracellular CD19 and limits antigen escape in B-cell malignancy. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03306-5

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03306-5

Keywords: ibrutinib, matriptase, CD19, antigen escape, B-cell malignancy, BTK inhibitor, CAR-T therapy, immunotherapy, Cell Death Discovery, serine protease, chronic lymphocytic leukemia, target preservation

Bruton tyrosine kinase, or BTK, sits at a critical junction in the B-cell receptor signaling pathway, and blocking it cripples the survival machinery of malignant lymphocytes. The first-generation inhibitor ibrutinib proved the concept, improving progression-free survival in relapsed or refractory disease, but its off-target activity produced troublesome cardiac events, bleeding, and other toxicities. Second-generation inhibitors zanubrutinib and acalabrutinib were engineered for greater selectivity, and clinical momentum has been rapid: acalabrutinib combined with bendamustine and rituximab recently earned preferred first-line status in the NCCN 2025 guideline after the ECHO trial demonstrated a complete response rate of 88.9 percent and a median progression-free survival of 28.6 months, while zanubrutinib gained a first-line indication restricted to TP53-mutant disease after Phase II trials recorded complete response rates of 88 percent in that high-risk cohort. Yet guidelines remained fragmented, because trial designs varied so widely that head-to-head conclusions were impossible without pooling the evidence.

To close that gap, investigators systematically searched PubMed, Cochrane, and Embase for studies published before January 31, 2025, identifying thousands of records: 715 studies touching acalabrutinib, 3,398 on ibrutinib, and 486 on zanubrutinib. After duplicate removal and rigorous screening by independent reviewers, 70 studies survived, comprising four randomized controlled trials, three retrospective-prospective observational studies, and 63 single-arm cohort studies. Together they encompassed 1,641 treatment-naïve patients and 1,791 patients with relapsed or refractory disease, with median ages ranging from 56 to 75 years in the newly diagnosed group and 61 to 74 years in the relapsed group. The analysis was registered with PROSPERO, conducted under PRISMA reporting standards, and quality was assessed with the Cochrane Risk of Bias 2 tool for randomized trials and the MINORS instrument for single-arm studies. Statistical pooling used random-effect models where heterogeneity exceeded an I-squared value of 50 percent, with sensitivity analyses and funnel plots, Egger’s test, and Begg’s test confirming the absence of publication bias.

The headline results are striking. In treatment-naïve patients, BTK inhibitor-based therapy achieved a pooled complete response rate of 76.5 percent and an objective response rate of 94.5 percent. In relapsed or refractory patients, the corresponding figures fell to 43.2 percent and 81.2 percent, illustrating how much harder the disease is to subdue once it has already weathered prior treatment. Subgroup analysis by drug type then revealed a clear hierarchy in the newly diagnosed setting: zanubrutinib delivered a complete response rate of 95.2 percent, acalabrutinib 89.3 percent, and ibrutinib only 61.3 percent, a statistically significant difference with a p-value of 0.0042. Objective response rates followed the same pattern, at 99.1 percent for zanubrutinib, 97.7 percent for acalabrutinib, and 90.0 percent for ibrutinib. In the relapsed setting, however, the three drugs performed comparably, with no significant differences in either complete response or objective response rates.

Safety data from 53 studies added crucial nuance. Hematologic toxicities dominated, with pooled rates of neutropenia around 28 to 34 percent, thrombocytopenia around 33 to 35 percent, and anemia between 16 and 20 percent across patient groups. Zanubrutinib-based therapy showed significantly lower rates of neutropenia in treatment-naïve patients and lower thrombocytopenia in relapsed patients than its two rivals. Infection emerged as the most common non-hematologic adverse event, affecting roughly a third of newly diagnosed patients and nearly 40 percent of relapsed patients, and zanubrutinib carried a notably higher infection rate of 66.1 percent in the relapsed setting. Ibrutinib, by contrast, was associated with a significantly elevated rate of cardiac events at 7.7 percent, compared with just 2.0 percent for acalabrutinib and 0.2 percent for zanubrutinib, while acalabrutinib showed the lowest hemorrhage rate at 9.3 percent. These safety profiles, combined with superior efficacy, argue strongly for the newer agents in frontline care.

The analysis also dissected how best to combine BTK inhibitors with other therapies, a question that has generated considerable confusion in the clinic. In newly diagnosed patients, triple regimens pairing a BTK inhibitor with an anti-CD20 monoclonal antibody and small-molecule agents such as venetoclax, lenalidomide, or proteasome inhibitors achieved a complete response rate of 88.0 percent and an objective response rate of 97.1 percent, numerically outperforming regimens built on traditional chemotherapy with or without stem cell transplantation, though the difference did not reach statistical significance. In relapsed disease, the most impressive complete response rates came from combining BTK inhibitors with CAR T-cell immunotherapy at 80.0 percent, and with anti-CD20 antibodies plus small-molecule therapy at 68.3 percent, both significantly better than monotherapy. Because only 20 patients in the entire dataset received the BTK inhibitor plus CAR-T combination, the authors urge caution in interpreting that result, but the signal is compelling.

The findings carry substantial biological and clinical logic. BTK inhibitor monotherapy rarely achieves deep, durable remissions, and acquired resistance eventually defeats many patients, particularly in the relapsed setting. Pairing BTK blockade with agents attacking complementary pathways, such as the BCL2 inhibitor venetoclax or immunomodulators like lenalidomide, addresses that vulnerability. An observational cohort study cited in the analysis showed that BTK inhibitor-venetoclax regimens could overcome the unfavorable prognosis of TP53-mutated disease, and the ENRICH trial demonstrated that ibrutinib plus rituximab outperformed standard immunochemotherapy with fewer grade 3 or higher adverse events in untreated patients. The meta-analysis now provides quantitative support for chemotherapy-free strategies, showing that small-molecule combinations can match or exceed chemotherapy-based regimens without their cumulative toxicity, a potentially transformative option for elderly and frail patients who cannot tolerate intensive chemoimmunotherapy.

The authors are candid about limitations. Most included studies were single-arm trials vulnerable to selection bias; heterogeneity was moderate to high, reflecting differences in patient demographics, TP53 status, treatment line, and follow-up duration; and most studies did not report progression-free or overall survival in analyzable form, precluding pooled survival analysis and leaving long-term benefit unproven. Nonetheless, the central conclusions stand on robust methodology: acalabrutinib and zanubrutinib are more promising than ibrutinib as first-line options, owing to superior response rates and more favorable safety profiles, and chemotherapy-free combination regimens can partially overcome the traditionally grim prognosis of relapsed disease. As BTK inhibitors continue to infiltrate frontline protocols, this synthesis offers clinicians a data-driven roadmap for sequencing therapy, and it sets a clear agenda for the randomized head-to-head trials that the field still sorely needs.

Subject of Research: Comparative efficacy and safety of Bruton tyrosine kinase inhibitors in treatment-naïve and relapsed/refractory mantle cell lymphoma

Article Title: Comparative Efficacy of BTK Inhibitors in Treatment‐Naïve and Relapsed/Refractory Mantle Cell Lymphoma: A Systematic Review and Meta‐Analysis

Article References: Xu, F., Zou, X., Yang, Y., Zhou, K., & Huang, W. (2026). Comparative Efficacy of BTK Inhibitors in Treatment‐Naïve and Relapsed/Refractory Mantle Cell Lymphoma: A Systematic Review and Meta‐Analysis. Journal of Cellular and Molecular Medicine, 30(17), Article e71340. https://doi.org/10.1111/jcmm.71340

Image Credits: AI Generated

DOI: 10.1111/jcmm.71340

Keywords: mantle cell lymphoma, BTK inhibitors, acalabrutinib, zanubrutinib, ibrutinib, meta-analysis, clinical trials, hematology, chemotherapy-free regimens, lymphoma treatment, venetoclax, CAR-T therapy